The FDA Group's CEO, Nick Capman, sits down with Donna Dorozinsky, founder and CEO of Just in Time GCP, to discuss key considerations for Trial Master File (TMF) management and GCP compliance.
Discussion points include:
Donna's top 5 takeaways:
Donna is a Registered Nurse and business consultant who has spent over 30 years in drug development with extensive experience in study operations, including clinical operations, safety, data management, biostatistics, clinical supply management, and TMF management.
Donna is a TMF Reference Model Steering Committee member and is a member of the Association of Women Entrepreneurs. She’s a founding member of the Society of Nurse Scientists, Innovators, Entrepreneurs, & Leaders. She serves on the Board of Trustees at Gwynedd Mercy University, where she received her BSN, and also has an MSN from Widener University.
Who is The FDA Group? The FDA Group helps life science organizations rapidly access the industry's best consultants, contractors, and candidates. Our resources assist in every stage of the product lifecycle, from clinical development to commercialization, with a focus in Quality Assurance, Regulatory Affairs, and Clinical Operations. https://www.thefdagroup.com/
Navigating Risk Management in Medical Devices with Brian Dense
The DEA, FDA & Controlled Substances: An Insider's Perspective with Former DEA Agent Dennis Wichern
A Deep Dive into Medical Device Regulatory Strategy with Regulatory Attorney Christine P. Bump
Lessons from a Medtech Entrepreneur: Ram Konduru on Fostering Teamwork and Personal Growth in Leadership
Unlocking Effective Leadership: A Conversation with MetaComet Systems President, David Marlin
Leadership, Management, and Enhancing Quality of Life: A Conversation with Dan Barker, CEO of Wikimotive
Navigating the 510(k) Process: A Q&A with Regulatory Consultant, Trey Thorsen, MS, RAC
The Future of Life Science Talent Acquisition: Securing In-Demand Skills in a Competitive Market
FDA Revives Its Proposed Quality Metrics Program for Pharma
Inspection Alternatives Are Driving More FDA Enforcement Actions: What It Means for Industry
FDA's Domestic Biopharma Inspections Return to Normal
Quality Management Review: Benchmarking Quantitatively!
Addressing FDA's Inspection Backlog with Mary Denigan-Macauley, GAO's Director of Health Care
FDA's Fraudulent Products Task Force and Operation Quack Hack Battle COVID Vaccine Scams
What to Expect for the FDA's Regulation of Medical Devices & Digital Health Under the Biden Administration
Clinical Outsourcing & Insourcing: Selecting the Right Model or Mix
What RA/QA/Clinical Leaders Should Expect From the FDA in 2021
Inside FDA Pre-Approval Inspections with Former FDA Investigator, Christopher Smith
A Look at FDA's Pandemic Inspections Q&A Guidance
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Unexplainable
Stuff To Blow Your Mind
Ground Truths